Citizens raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $155 from $152 and keeps an Outperform rating on the shares. FDA approval for hypothalamic obesity substantially expands Imcivree’s commercial potential, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals trading resumes
- Rhythm Pharmaceuticals trading halted, news pending
- Rhythm Pharmaceuticals: EMANATE Setback but Validated MC4R Mechanism and Pipeline Optionality Support Lowered $100 Buy Rating
- Rhythm price target lowered to $100 from $110 at H.C. Wainwright
- Rhythm Pharmaceuticals price target lowered to $130 from $140 at RBC Capital